Electronic Resource
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
| العنوان: | Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. |
|---|---|
| المؤلفون: | McQuilten Z.K., Busija L., Seymour J.F., Stanworth S., Wood E.M., Kenealy M., Weinkove R. |
| بيانات النشر: | Taylor and Francis Ltd. United Kingdom 2021-12-29 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Myelodysplastic syndromes (MDS) have a major impact on quality of life (QoL). We performed a post hoc analysis of two multicenter trials of azacitidine-based disease-modifying therapy for patients with MDS and low blast count acute myeloid leukemia (AML), to identify factors associated with QoL. 231 patients were included (median age 70 years). At baseline, higher initial hemoglobin, but not neutrophil or platelet count, was associated with better global QoL and physical function (p < 0.001 and p = 0.001, respectively). During therapy, increase in hemoglobin was associated with improvement in QoL and physical function (p = 0.005 and p < 0.001, respectively). Lower initial hemoglobin was associated with higher dyspnea and fatigue scores (p < 0.001 and p = 0.001, respectively), and hemoglobin response was associated with improvement in dyspnea and fatigue (p < 0.001 for each). In patients with MDS and low blast count AML, hemoglobin level was strongly correlated with global QoL, physical functioning, dyspnea and fatigue, both before and during azacitidine-based therapy.Copyright © 2021 Informa UK Limited, trading as Taylor & Francis Group. |
| مصطلحات الفهرس: | Article |
| URL: | Leukemia and Lymphoma LibKey Link |
| الاتاحة: | Open access content. Open access content |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/45097 Leukemia and Lymphoma. (no pagination), 2021. Date of Publication: 2021. https://repository.monashhealth.org/monashhealthjspui/handle/1/45097 Haematology Monash Health https://dx.doi.org/10.1080/10428194.2021.2012664 (McQuilten, Wood) Department of Haematology, Monash Health, Melbourne, Australia (McQuilten, Busija, Wood) Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (Seymour) Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia (Seymour) Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (Stanworth) Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (Stanworth) Clinical Department, NHS Blood and Transplant, Oxford, United Kingdom (Stanworth) Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom (Kenealy) Cabrini Health, Melbourne, Australia (Kenealy) Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia (Weinkove) Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand (Weinkove) Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand (Weinkove) Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand (McQuilten, Busija, Wood) Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (Seymour) Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia (Seymour) Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (Stanworth) Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (Stanworth) Clinical Department, NHS Blood and Transplant, Oxford, United Kingdom (Stanworth) Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom (Kenealy) Cabrini Health, Melbourne, Australia (Kenealy) Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia (Weinkove) Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand (Weinkove) Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand (Weinkove) Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand (McQuilten, Wood) Department of Haematology, Monash Health, Melbourne, Australia 1305133529 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305133529 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |